BioSpace News Archive

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced its operating and financial results for the first quarter 2023.

aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 2023 RBC Capital Markets Global Healthcare Conference, which is scheduled to take place May 16 – 17, 2023, in New York, NY.

Viracta Therapeutics, Inc. announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT.

NeuroOne Medical Technologies Corporation, a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces its operating results for the fiscal second quarter 2023 ended March 31, 2023.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

IntelGenx Technologies Corp. reported financial results for the first quarter ended March 31, 2023.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced the publication of the results of its US multicenter pilot trial in JAMA Network Open.

Journey Medical Corporation announced that it has postponed the release of its first fiscal quarter financial results and conference call, previously scheduled for Thursday, May 11, 2023, to provide additional time to complete the finalization of its financial statements.